A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients

Wu, Ximei; Sheng, Hongxu; Wang, Luming; Xia, Pinghui; Wang, Yiqing; Yu, Li; Lv, Wang; Hu, Jian

doi:10.18632/aging.202761

Cited by 13 publications

(11 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, low m 6 A score, characterized by increased mutation burden and activation of immunity, indicates an inflamed TME phenotype and enhanced response to anti-PD-1/L1 immunotherapy in gastric cancer (GC) (65). In addition, m 6 A-related signature has been identified as biomarker for tumor immune phenotypes and anti-PD-1 immunotherapy treatment response in lung adenocarcinoma (LADC) (72,73), stomach adenocarcinomas (STADs) (74), Esophageal squamous cell carcinoma (ESCC) (75,76), Renal Papillary Cell Carcinoma (RPCC), Hepatocellular Carcinoma (HCC) (77,78). These statistic results together indicate that m 6 A modification may reflect TME status and predict immunotherapy efficacy in pan-cancers instead of limited to specific cancer types.…”

Section: Role Of M 6 a In Tme Immune Responsementioning

confidence: 99%

N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target

Quan

Othmane

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

N6-methylation of adenosine (m6A), a post-transcriptional regulatory mechanism, is the most abundant nucleotide modification in almost all types of RNAs. The biological function of m6A in regulating the expression of oncogenes or tumor suppressor genes has been widely investigated in various cancers. However, recent studies have addressed a new role of m6A modification in the anti-tumor immune response. By modulating the fate of targeted RNA, m6A affects tumor-associated immune cell activation and infiltration in the tumor microenvironment (TME). In addition, m6A-targeting is found to affect the efficacy of classical immunotherapy, which makes m6A a potential target for immunotherapy. Although m6A modification together with its regulators may play the exact opposite role in different tumor types, targeting m6A regulators has been shown to have wide implications in several cancers. In this review, we discussed the link between m6A modification and tumor with an emphasis on the importance of m6A in anti-tumor immune response and immunotherapy.

show abstract

Section: Role Of M 6 a In Tme Immune Responsementioning

confidence: 99%

N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target

Quan

Othmane

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Multiple studies have performed exhaustive analyses of the relationship between m6A regulator expression and epidemiological data of cancer patients from TCGA. Among the cancer types examined were colorectal cancer (35), hepatocellular carcinoma (36), and lung adenocarcinoma (37). At present, there are no studies on the correlation between m6A regulator expression and ESCC prognosis.…”

Section: Discussionmentioning

confidence: 99%

Estimating the prognosis of esophageal squamous cell carcinoma based on The Cancer Genome Atlas (TCGA) of m6A methylation-associated genes

Pan¹,

Lu²,

Yang³

et al. 2022

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: N6-methyladenosine (m6A) mRNA modification is the most prevalent in certain tumors. However, its expression profile and prognostic value in human esophageal squamous cell carcinoma (ESCC) remains unknown.Methods: Herein, we performed an extensive investigation of the m6A-associated gene expression profile and determined its significance in the prognosis of ESCC. We received the RNA expression profiles of 81 ESCC tissues and one normal esophageal tissue from The Cancer Genome Atlas (TCGA) database.Kaplan-Meier (KM) survival analysis was used to assess the predictability of m6A methylation-associated gene expression in ESCC prognosis. In addition, univariate and multivariate Cox regression, as well as least absolute shrinkage and selection operator (LASSO) regression models were employed for the establishment of prognostic signatures. Lastly, KM survival analysis, proportional hazard models, and receiver operating characteristic (ROC) curves were used to verify the prognostic value. Moreover, we also investigated the associations among the m6A prognostic signature, immune cell infiltration, and programmed cell deathligand 1 (PD-L1) expression.

show abstract

“…Wu et al [ 17 ] used univariate and LASSO Cox regression analysis to develop a m6A regulator prognostic signature composed of HNRNPC, METTL3, HNRNA2B1, IGF2BP1, and IGF2BP2 for lung adenocarcinoma based on RNA-seq, clinicopathological, and single nucleotide variation data retrieved from the TCGA database. [ 17 ] Also, Yang et al [ 18 ] found that HNRNPC and KIAA1429 can be regarded as potential prognostic markers in papillary renal cell carcinoma by using the similar method. However, only few studies have investigated the prognostic value of m6A regulators in UCEC.…”

Section: Discussionmentioning

confidence: 99%

Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis

et al. 2021

View full text Add to dashboard Cite

N6-methyladenosine (m6A) methylation is proved to play a significant role in human cancers. This study aimed to explore the association between m6A ribonucleic acid (RNA) methylation regulators and uterine corpus endometrial carcinoma (UCEC), and build a prognostic signature of m6A regulators for UCEC. RNA-seq transcriptome data and clinicopathological data of UCEC were downloaded from the Cancer Genome Atlas database. We compared the expression of 23 m6A-regulators in tumor tissues and nontumor tissues. Then we classified the data into 3 clusters by consensus clustering analysis. Several regulators were picked out as the prognostic signature of patients with UCEC based on least absolute shrinkage and selection operator Cox regression analysis. Additionally, we established a predictive nomogram to calculate survival times. Finally, we used receiver operating characteristic curve, univariate Cox regression analysis, and multivariate Cox regression analysis to further verify the prognostic value of the risk signature consisting of m6A regulators. The expression of 18/23 m6A regulators was significantly different in UCEC compared with normal samples. Gene ontology functional analysis of these regulators revealed that they were mainly participated in RNA splicing, stabilization, modification, and degradation. LRPPRC, IGFBP2, KIAA1429, IGFBP3, FMR1, YTHDF1, METTL14, and YTHDF2 were selected to construct the risk signature and predictive nomogram. The results of receiver operating characteristic curve, univariate Cox regression analysis, and multivariate Cox regression analysis for the risk signature showed a good predictive performance for UCEC. The risk signature of 8-m6A regulators has potential prognostic value for patients with UCEC.

show abstract

A five-m6A regulatory gene signature is a prognostic biomarker in lung adenocarcinoma patients

Cited by 13 publications

References 93 publications

N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target

N6-Methyladenosine in Cancer Immunotherapy: An Undervalued Therapeutic Target

Estimating the prognosis of esophageal squamous cell carcinoma based on The Cancer Genome Atlas (TCGA) of m6A methylation-associated genes

Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis

Contact Info

Product

Resources

About